More Biopharma Patent Murkiness Ahead
Executive Summary
Drug makers were hoping the Supreme Court would take up diagnostic manufacturer Sequenom Inc.'s appeal to better clarify US patent laws. But the high court on June 27 declined to hear the case – meaning there's more murkiness ahead in determining how solid the protections are for US innovators' intellectual property.